$10.830
-0.459 (-4.24%)At close
VIR News
VIR Events
Olema Appoints Jason O'Byrne as CFO
Olema (OLMA) announced the appointment of Jason O'Byrne as CFO. O'Byrne brings more than two decades of finance and global operations leadership across high-growth biotechnology and pharmaceutical organizations. He joins Olema from Vir Biotechnology (VIR), where he served as executive VP and CFO.
Vir Reports Q2 Revenue of $238.9M, Exceeds Expectations
Reports Q2 revenue $238.9M, consensus $225.57M. Based on its current operating plans, including the net effects of the Astellas global collaboration, the company expects its cash, cash equivalents and investments to fund operations into the second half of 2028. Vir said, "This is a pivotal time for the CHD community, when availability of new therapies could improve awareness, testing and access to care. At EASL, experts emphasized that achieving durable suppression of hepatitis delta virus to undetectable levels is a key predictor of improved clinical outcomes for people with CHD. Our Week 96 SOLSTICE results demonstrate the potential of our dual-acting elebsiran and tobevibart combination regimen to rapidly achieve undetectable virus in most patients and raise the bar for treatment of this devastating condition. Beyond CHD, we remain focused on rapid execution of our joint clinical program with Astellas in prostate cancer and have initiated monotherapy and combination therapy dose-expansion cohorts in our VIR-5500 Phase 1 study that will help inform pivotal trial design."
Vir Biotechnology Appoints Brent Sabatini as Interim CFO
Vir Biotechnology announced that Brent Sabatini, SVP and Chief Accounting Officer, has been appointed Interim Principal Financial Officer. Jason O'Byrne is leaving the Company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition. The Company has initiated a comprehensive search to identify its next CFO.
Vir Biotechnology to Present New Therapy Data at EASL 2026
Vir Biotechnology "announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026. Tobevibart and elebsiran are investigational agents being evaluated as a novel combination regimen administered monthly as two separate sequential subcutaneous injections for the treatment of CHD. The combination is designed to disrupt the HDV life cycle at multiple points by addressing both viral entry and the sustained presence of hepatitis B surface antigen (HBsAg) that enables ongoing HDV replication. Tobevibart is an investigational broadly neutralizing monoclonal antibody (mAb) targeting HBsAg. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart was identified using Vir Biotechnology's proprietary mAb discovery platform. The Fc domain has been engineered to increase immune engagement and clearance of HBsAg immune complexes and incorporates Xencor's Xtend(TM) technology to extend half-life. Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) licensed from Alnylam Pharmaceuticals, Inc. It is designed to degrade hepatitis B virus RNA transcripts and limit the production of HBsAg."
Vir Bio Signs Global Agreement with Astellas to Advance Prostate Cancer Treatment
"Vir Bio delivered incredible momentum during the first quarter with positive, new VIR-5500 Phase 1 data and execution of a global agreement with Astellas in prostate cancer. The closing of our collaboration with Astellas in April has ignited the next stage of development work, bolstering our ability to move faster and think bigger together," said Marianne De Backer, Chief Executive Officer of Vir Biotechnology. "We also announced promising updated Phase 2 data on our combination regimen in CHD and will be presenting complete Week 96 data at the EASL Congress later this month. CHD is the most severe form of hepatitis. We believe our well-tolerated combination regimen is uniquely positioned to change the standard of care, bringing together robust efficacy with the potential for self-administration at home with once monthly subcutaneous dosing."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.